Bibeau Frédéric, Frugier Hélène, Denouël Amélie, Massemin Blandine, Boissière Florence
Service de pathologie, CRLCC Val-d'Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex 5.
Bull Cancer. 2008 Oct;95(10):995-1001. doi: 10.1684/bdc.2008.0734.
The pathologist's role in 2008 includes diagnosic, prognostic and predictive implications. Histopathologic criteria are still essential to manage the disease of cancer patients. They need to be based on standardized pathology reports and can use ancillary techniques such as immunohistochemistry and molecular biology. However, all the criteria used are not sufficient enough to provide accurate prognostic and predictive parameters for every patient and disease. This is the reason why translational studies more often involve the pathologist in prospective trials. The modern pathology is really integrated in this strategy, in terms of multidisciplinary approach, tumor banking, tissue microarray, molecular biology and new fixatives developments. All these subjects are discussed in this review article.
病理学家在2008年所扮演的角色涵盖诊断、预后及预测方面的意义。组织病理学标准对于管理癌症患者的疾病依然至关重要。这些标准需基于标准化的病理报告，并可采用免疫组织化学和分子生物学等辅助技术。然而，所使用的所有标准都不足以针对每一位患者和疾病提供准确的预后及预测参数。这就是转化研究为何更频繁地让病理学家参与前瞻性试验的原因。就多学科方法、肿瘤库、组织微阵列、分子生物学以及新型固定剂的研发而言，现代病理学确实融入了这一策略。本文综述将对所有这些主题展开讨论。
